Lakefront Biotherapeutics (GLPGF) Convertible Debt (2025 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly Convertible Debt came in at $25.3 million in Q1 2026, up 2.48% quarter-over-quarter from $24.6 million in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Convertible Debt (2025 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Convertible Debt for 2 consecutive years, with $25.3 million the latest figure, recorded in Q1 2026.
- On a quarterly basis, Convertible Debt changed N/A year-over-year to $25.3 million in Q1 2026; TTM through Mar 2026 was $25.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $23.9 million, changed N/A from the prior year.
- Convertible Debt was $25.3 million for Q1 2026 at Lakefront Biotherapeutics, up from $24.6 million in the prior quarter.
- Over five years, Convertible Debt peaked at $25.3 million in Q1 2026 and troughed at $23.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 25.26 Mn |
| Dec 31, 2025 | 24.65 Mn |
| Sep 30, 2025 | 24.28 Mn |
| Jun 30, 2025 | 23.03 Mn |